Category: Cancer

David B. Samadi, a doctor who practices at Lenox Hill Hospital located in New York City ,is the Chairman of Urology and Chief of Robotic Surgery and a member of the American Urological Association as well as the American Medical Association. His duties include diagnosis of cancer relating to the prostate, kidney, and bladder as well as treatment for these diseases and other urologic disorders.

Dr. David B. Samadi is skilled in the art of robotic surgery. He has used laparoscopic robotic radical prostatectomy and laparoscopic radical prostatectomy on thousands of patients. This type of robotic surgery is minimally invasive compared to some traditional treatments.

Educated at Stony Brook University, Samadi graduated with a biochemistry degree then continued onto Stony Brook School of Medicine. Furthering his education, he took postgraduate training from Montefiore Medical Center and Albert Einstein College of Medicine and finished a fellowship in proctology at Memorial Sloan Kettering Cancer Center.

Dr. David B. Samadi began his career in robotics at Henri Mondor Hospital Creteil, France. He was in a robotic radical prostatectomy fellowship. Not limiting himself to Europe and the United States, Samadi has performed surgery in 45 countries around the globe.

Early detection, coupled with diagnosis and treatment of prostate cancer is something Dr. Samadi strongly believes in and works on educating patients and the public. He has been a host on Fox, sharing his knowledge on the subject as a medical advisor on Sunday Housecall.

Not satisfied with television alone, Dr. Samadi created SamadiMD.com to help share his medical insight and updates people with new technologies, alternative treatments, and other health concerns men may face, such as fertility and regulating testosterone. He also launched a radio show in 2015.

Today, he is working on a modern approach to remove the prostate, which has been named the Samadi Modified Advanced Robotic Technique, or SMART, surgery. Other extremely successful creations are the most efficient OR team in America. He made it possible for a one robot to perform five prostate surgeries in a day. He manages his operating room staff like a baseball team, he says, “Everyone knows their position.”

While Dr. David B. Samadi has used his talents in robotics and enhance the quality of lives for many human beings, he looks to the future, which holds telesurgery, remote surgeries to advance the art of robotics in medicine.

Tempus is a company co-founded by Eric Lefkofsky, what they do is assist doctors in treating cancer more effectively. The approach is know as data driven cancer care, but what does this mean? Tempus is a technology company that has created a large library of molecular and clinical data, paired with an operating system to make this data both useable and accessible. Their approach utilizes genomic and transcriptomic sequences that have been analyzed in a lab, to allow doctors to understand individual patient’s tumors more completely. Through analyzing molecular and clinical data, personalized treatment options can be uncovered. Detailed reports, highlighting actionable insights and what impact they can provide for the patient, are provided to medical staff. Additionally, Tempus collaborates with researchers and doctors to develop automation and cell culture technology to allow screening of therapies with in synthetic or animal models not patients. Tempus has worked with the Mayo Clinic, Penn Medicine, Northwestern Medical, Pancreatic Cancer Action Network, and Rush University Medical Center among others.

Such an endeavor requires dedicated leaders and staff to make these ambitious goals a reality. One such individual at Tempus is the CEO, Eric Lefkofsky. Eric Lefkofsky believes this approach to cancer treatment will empower doctors to make live changing, decisions based on an individuals data, made at a molecular level in real time. Tempus hopes to be involved in some of the thousands of clinical trials going on continuously and contribute significant advancements in target therapy.

Mr. Lefkofsky graduated from the University of Michigan and received his Juris Doctor at University of Michigan Law School. He has been involved in a number of companies over the years. He also co-founded Lightbank, a venture fund investing in technology companies; Groupon, a global e-commerce marketplace; Uptake Technologies, a predictive analytical platform for large industries.

Mediaocean, and Echo Global Logistics. He and his wife co-chair the Lefkofsky Family Foundation which has given generously to numerous cancer research facilities over the years. He serves as a Trustee of Lurie Children’s Hospital of Chicago, The Museum of Science and Industry, The Art Institute of Chicago and World Business Chicago.